KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Research & Development (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Research & Development for 4 consecutive years, with $144.3 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Research & Development fell 50.26% year-over-year to $144.3 million, compared with a TTM value of $745.9 million through Jun 2023, down 54.84%, and an annual FY2025 reading of $243.8 million, down 42.51% over the prior year.
  • Research & Development was $144.3 million for Q2 2023 at Ginkgo Bioworks Holdings, down from $162.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $985.0 million in Q4 2021 and bottomed at $36.1 million in Q3 2020.
  • Average Research & Development over 4 years is $231.4 million, with a median of $162.6 million recorded in 2023.
  • Peak annual rise in Research & Development hit 457.47% in 2022, while the deepest fall reached 81.61% in 2022.
  • Year by year, Research & Development stood at $36.1 million in 2020, then soared by 2630.87% to $985.0 million in 2021, then tumbled by 81.61% to $181.2 million in 2022, then dropped by 20.35% to $144.3 million in 2023.
  • Business Quant data shows Research & Development for DNA at $144.3 million in Q2 2023, $162.6 million in Q1 2023, and $181.2 million in Q4 2022.